The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Thrombophilia, Clinical Factors, and Recurrent Venous Thrombotic Events
Abstract
CONTEXT: Data on the recurrence rate of venous thrombotic events and the effect of several risk factors, including thrombophilia, remain controversial. The potential benefit of screening for thrombophilia with respect to prophylactic strategies and duration of anticoagulant treatment is not yet known. OBJECTIVES: To estimate the recurrence rate of thrombotic events in patients after a first thrombotic event and its determinants, including thrombophilic abnormalities. DESIGN, SETTING, AND PATIENTS: Prospective follow-up study of 474 consecutive patients aged 18 to 70 years without a known malignancy treated for a first objectively confirmed thrombotic event at anticoagulation clinics in the Netherlands. The Leiden Thrombophilia Study (LETS) was conducted from 1988 through 1992 and patients were followed up through 2000. MAIN OUTCOME MEASURES: Recurrent thrombotic event based on thrombophilic risk factors, sex, type of initial thrombotic event (idiopathic or provoked), oral contraceptive use, elevated levels of factors VIII, IX, XI, fibrinogen, homocysteine, and anticoagulant deficiencies. RESULTS: A total of 474 patients were followed up for mean (SD) of 7.3 (2.7) years and complete follow-up was achieved in 447 (94%). Recurrence of thrombotic events occurred in 90 patients during a total of 3477 patient-years. The rate of thrombotic event recurrence was 25.9 per 1000 patient-years (95% confidence interval [CI], 20.8-31.8 per 1000 patient-years). The incidence rate of recurrence was highest during the first 2 years (31.9 per 1000 patient-years; 95% CI, 20.3-43.5 per 1000 patient-years). The risk of thrombotic event recurrence was 2.7 times (95% CI, 1.8-4.2 times) higher in men than in women. Patients whose initial thrombotic event was idiopathic had a higher risk of a thrombotic event recurrence than patients whose initial event was provoked (hazard ratio [HR], 1.9; 95% CI, 1.2-2.9). Women who used oral contraceptives during follow-up had a higher thrombotic event recurrence rate (28.0 per 1000 patient-years; 95% CI, 15.9-49.4 per 1000 patient-years) than those who did not (12.9 per 1000 patient-years; 95% CI, 7.9-21.2 per 1000 patient-years). Recurrence risks of a thrombotic event by laboratory abnormality ranged from an HR of 0.6 (95% CI, 0.3-1.1) in patients with elevated levels of factor XI to an HR of 1.8 (95% CI, 0.9-3.7) for patients with anticoagulant deficiencies. CONCLUSIONS: Prothrombotic abnormalities do not appear to play an important role in the risk of a recurrent thrombotic event. Testing for prothrombotic defects has little consequence with respect to prophylactic strategies. Clinical factors are probably more important than laboratory abnormalities in determining the duration of anticoagulation therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutation in blood coagulation factor V associated with resistance to activated protein C
Bertina, R. M., Koeleman, B. P. C., Koster, T., Rosendaal, F. R., Dirven, R. J., de Ronde, H., van der Velden, P. A., & Reitsma, P. H. (1994) · Nature · doi:10.1038/369064a0 · Cited by 3,783
Poort, Sr., Rosendaal, F., Reitsma, P., & Bertina, R. (1996) · Blood · doi:10.1182/blood.v88.10.3698.bloodjournal88103698 · Cited by 3,079
The Long-Term Clinical Course of Acute Deep Venous Thrombosis
Prandoni, P., Lensing, A. W. A., Cogo, A., Cuppini, S., Villalta, S., Carta, M., Cattelan, A. M., Polistena, P., Bernardi, E., & Prins, M. H. (1996) · Annals of Internal Medicine · doi:10.7326/0003-4819-125-1-199607010-00001 · Cited by 2,109
Anderson, F. A. (1991) · Archives of Internal Medicine · doi:10.1001/archinte.1991.00400050081016 · Cited by 1,669
Koster, T., Vandenbroucke, J., Rosendaal, F., de Ronde, H., Briët, E., & Bertina, R. (1993) · The Lancet · doi:10.1016/s0140-6736(05)80081-9 · Cited by 1,239
Koster, T., Vandenbroucke, J. P., Rosendaal, F. R., Briët, E., Rosendaal, F. R., & Blann, A. D. (1995) · The Lancet · doi:10.1016/s0140-6736(95)90166-3 · Cited by 1,131
Kearon, C., Gent, M., Hirsh, J., Weitz, J., Kovacs, M. J., Anderson, D. R., Turpie, A. G., Green, D., Ginsberg, J. S., Wells, P., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903253401201 · Cited by 1,072
Hyperhomocysteinemia as a Risk Factor for Deep-Vein Thrombosis
den Heijer, M., Koster, T., Blom, H. J., Bos, G. M. J., Briët, E., Reitsma, P. H., Vandenbroucke, J. P., & Rosendaal, F. R. (1996) · New England Journal of Medicine · doi:10.1056/nejm199603213341203 · Cited by 1,044
Rosendaal, F., Koster, T., Vandenbroucke, J., & Reitsma, P. (1995) · Blood · doi:10.1182/blood.v85.6.1504.bloodjournal8561504 · Cited by 1,004
A prospective study of the incidence of deep‐vein thrombosis within a defined urban population
NORDSTRÖM, M., LINDBLAD, B., BERGQVIST, D., & KJELLSTRÖM, T. (1992) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.1992.tb00565.x · Cited by 777
High plasma levels of factor VIII and the risk of recurrent venous thromboembolism
Kyrle, P. A., Minar, E., Hirschl, M., Bialonczyk, C., Stain, M., Schneider, B., Weltermann, A., Speiser, W., Lechner, K., & Eichinger, S. (2000) · New England Journal of Medicine · doi:10.1056/nejm200008173430702 · Cited by 763
High Levels of Coagulation Factor XI as a Risk Factor for Venous Thrombosis
Meijers, J. C. M., Tekelenburg, W. L. H., Bouma, B. N., Bertina, R. M., & Rosendaal, F. R. (2000) · New England Journal of Medicine · doi:10.1056/nejm200003093421004 · Cited by 700
Baglin, T., Luddington, R., Brown, K., & Baglin, C. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14111-6 · Cited by 694
Recurrent Venous Thromboembolism After Deep Vein Thrombosis: Incidence and Risk Factors
Hansson, P.-O., Sörbo, J., & Eriksson, H. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.6.769 · Cited by 590
Residual Venous Thrombosis as a Predictive Factor of Recurrent Venous Thromboembolism
Prandoni, P., Lensing, A. W. A., Prins, M. H., Bernardi, E., Marchiori, A., Bagatella, P., Frulla, M., Mosena, L., Tormene, D., Piccioli, A., et al. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-12-200212170-00008 · Cited by 547
De Stefano, V., Martinelli, I., Mannucci, P. M., Paciaroni, K., Chiusolo, P., Casorelli, I., Rossi, E., & Leone, G. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909093411104 · Cited by 482
The Risk of Recurrent Venous Thromboembolism in Men and Women
Kyrle, P. A., Minar, E., Bialonczyk, C., Hirschl, M., Weltermann, A., & Eichinger, S. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032959 · Cited by 477
High levels of factor IX increase the risk of venous thrombosis
Vlieg, A. V. H., van der Linden, I. K., Bertina, R. M., & Rosendaal, F. R. (2000) · Blood · doi:10.1182/blood.v95.12.3678 · Cited by 404
Risk Factors for Venous Thrombotic Disease
Rosendaal, F. R. (1999) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1615887 · Cited by 375
Simioni, P., Prandoni, P., Lensing, A. W. A., Scudeller, A., Sardella, C., Prins, M. H., Villalta, S., Dazzi, F., & Girolami, A. (1997) · New England Journal of Medicine · doi:10.1056/nejm199702063360602 · Cited by 368
Is hyperhomocysteinaemia a risk factor for recurrent venous thrombosis?
den Heijer, M., Gerrits, W. B. J., Haak, H. L., Wijermans, P. W., Bos, G. M. J., Blom, H. J., & Rosendaal, F. R. (1995) · The Lancet · doi:10.1016/s0140-6736(95)90008-x · Cited by 367
Koster, T., Rosendaal, F., Briet, E., van der Meer, F., Colly, L., Trienekens, P., Poort, Sr., Reitsma, P., & Vandenbroucke, J. (1995) · Blood · doi:10.1182/blood.v85.10.2756.bloodjournal85102756 · Cited by 364
Koster, T., Rosendaal, F. R., Reitsma, P. H., Velden, P. A. V. D., Briët, E., & Vandenbroucke, J. P. (1994) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1642511 · Cited by 293
The Leiden Thrombophilia Study (LETS)
Meer, F. J. M. V. D., Koster, T., Vandenbroucke, J. P., Briët, E., & Rosendaal, F. R. (1997) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1657602 · Cited by 275
Hyperhomocysteinemia is a risk factor of recurrent venous thromboembolism.
Eichinger, S., Stümpflen, A., Hirschl, M., Bialonczyk, C., Herkner, K. R., STAIN, M., Schneider, B., Pabinger, I., Lechner, K., & Kyrle, P. A. (1998) · PubMed · Cited by 250
Factor V Leiden and Risks of Recurrent Idiopathic Venous Thromboembolism
Ridker, P. M., Miletich, J. P., Stampfer, M. J., Goldhaber, S. Z., Lindpaintner, K., & Hennekens, C. H. (1995) · Circulation · doi:10.1161/01.cir.92.10.2800 · Cited by 243
The diagnosis of acute, recurrent, deep-vein thrombosis: a diagnostic challenge.
Hull, R. D., Carter, C. J., Jay, R. M., Ockelford, P. A., Hirsch, J., Turpie, A. G., Zielinsky, A., Gent, M., & Powers, P. J. (1983) · Circulation · doi:10.1161/01.cir.67.4.901 · Cited by 218
Schulman, S., Sten-Linder, M., Wiman, B., Egberg, N., Johnsson, H., Lindmarker, P., & and the DURAC Trial Study Group (1999) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1614554 · Cited by 212
The Risk of Recurrent Venous Thromboembolism in Patients with and without Factor V Leiden
Eichinger, S., Pabinger, I., Stümpfien, A., Hirschl, M., Bialonczyk, C., Schneider, B., Mannhalter, C., Minar, E., Lechner, K., & Kyrle, P. A. (1997) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1656023 · Cited by 203
Minar, E., Hirschl, M., Bialonczyk, C., Stain, M., Mannhalter, C., Stümpflen, A., Schneider, B., Lechner, K., Kyrle, P. A., & Eichinger, S. (1999) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1614409 · Cited by 131
High risk of recurrent venous thromboembolism in men
Baglin, T. P., Luddington, R. J., Brown, K., & Baglin, C. (2004) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2004.01050.x · Cited by 128
Simioni, P., Prandoni, P., Lensing, A. W. A., Manfrin, D., Tormene, D., Gavasso, S., Girolami, B., Sardella, C., Prins, M. H., & Girolami, A. (2000) · Blood · doi:10.1182/blood.v96.10.3329 · Cited by 126
The risk of recurrent venous thromboembolism among patients with high factor IX levels
Weltermann, A., Eichinger, S., Bialonczyk, C., Minar, E., Hirschl, M., Quehenberger, P., Schönauer, V., & Kyrle, P. A. (2003) · Journal of Thrombosis and Haemostasis · doi:10.1046/j.1538-7836.2003.00038.x · Cited by 102
Stefano, V. D., Martinelli, I., Mannucci, P. M., Paciaroni, K., Rossi, E., Chiusolo, P., Casorelli, I., & Leone, G. G. M. (2001) · British Journal of Haematology · doi:10.1046/j.1365-2141.2001.02827.x · Cited by 90
G20210A mutation in the prothrombin gene and the risk of recurrent venous thromboembolism
Miles, J. S., Miletich, J. P., Goldhaber, S. Z., Hennekens, C. H., & Ridker, P. M. (2001) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)01080-9 · Cited by 88
Eichinger, S., Weltermann, A., Mannhalter, C., Minar, E., Bialonczyk, C., Hirschl, M., Schönauer, V., Lechner, K., & Kyrle, P. A. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.20.2357 · Cited by 83
Simioni, P. (2003) · Journal of Thrombosis and Haemostasis · doi:10.1046/j.1538-7836.2003.00094.x · Cited by 14
Cited by
Kearon (2012) · doi:10.1378/chest.11-2301 · Cited by 6,119
Antithrombotic Therapy for VTE Disease
Kearon, C., Akl, E. A., Ornelas, J., Blaivas, A., Jimenez, D., Bounameaux, H., Huisman, M., King, C. S., Morris, T. A., Sood, N., et al. (2016) · Chest · doi:10.1016/j.chest.2015.11.026 · Cited by 4,830
Meschia, J. F., Bushnell, C., Boden-Albala, B., Braun, L. T., Bravata, D. M., Chaturvedi, S., Creager, M. A., Eckel, R. H., Elkind, M. S. V., Fornage, M., et al. (2014) · Stroke · doi:10.1161/str.0000000000000046 · Cited by 2,650
Antithrombotic Therapy for Venous Thromboembolic Disease
Kearon, C., Kahn, S. R., Agnelli, G., Goldhaber, S., Raskob, G. E., & Comerota, A. J. (2008) · Chest · doi:10.1378/chest.08-0658 · Cited by 1,996
Goldstein, L. B., Bushnell, C. D., Adams, R. J., Appel, L. J., Braun, L. T., Chaturvedi, S., Creager, M. A., Culebras, A., Eckel, R. H., Hart, R. G., et al. (2011) · Stroke · doi:10.1161/str.0b013e3181fcb238 · Cited by 1,306
Metadata
- Authors
- Christiansen, S. C.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2005-05-18
- Volume
- 293
- Issue
- 19
- Pages
- 2352
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2047438580
- Cited by
- 586
- References
- 38
- FWCI
- 19.63
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.